SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-23-019739
Filing Date
2023-05-09
Accepted
2023-05-09 16:27:15
Documents
52
Period of Report
2023-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q virx-20230331.htm   iXBRL 10-Q 2411692
2 EX-31.1 virx-ex31_1.htm EX-31 13512
3 EX-31.2 virx-ex31_2.htm EX-31 13518
4 EX-32.1 virx-ex32_1.htm EX-32 6244
5 EX-32.2 virx-ex32_2.htm EX-32 6180
  Complete submission text file 0000950170-23-019739.txt   9284272

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT virx-20230331_lab.xml EX-101.LAB 539790
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT virx-20230331_def.xml EX-101.DEF 278514
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT virx-20230331_cal.xml EX-101.CAL 40260
9 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT virx-20230331.xsd EX-101.SCH 64666
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT virx-20230331_pre.xml EX-101.PRE 405653
46 EXTRACTED XBRL INSTANCE DOCUMENT virx-20230331_htm.xml XML 1890785
Mailing Address 2533 S COAST HWY 101 SUITE 210 CARDIFF CA 92007
Business Address 2533 S COAST HWY 101 SUITE 210 CARDIFF CA 92007 858-400-8470
Viracta Therapeutics, Inc. (Filer) CIK: 0001061027 (see all company filings)

IRS No.: 943295878 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-51531 | Film No.: 23902520
SIC: 2834 Pharmaceutical Preparations